• Age: ≥ 18 years old;

• Patients with nasopharyngeal carcinoma diagnosed by pathology (including histology or cytology), with a clinical stage of III - IV (excluding T3N0 - 1) (according to the UICC/AJCC TNM staging system (8th edition));

• No prior systematic treatment (surgery, radiotherapy, chemotherapy, etc.); At least one measurable lesion on imaging examination (according to RECIST criteria version 1.1);

• ECOG PS: 0 - 1 points;

• Expected survival time ≥ 3 months;

• Normal function of major organs, meeting the following criteria:

‣ Blood routine tests should meet the following (without blood transfusion within 14 days):

• HB ≥ 100 g/L,

∙ WBC ≥ 3 × 10⁹/L,

∙ ANC ≥ 1.5 × 10⁹/L,

∙ PLT ≥ 100 × 10⁹/L;

⁃ Biochemical tests should meet the following criteria:

• BIL \< 1.5 times the upper limit of normal (ULN),

∙ ALT and AST \< 2.5 ULN, GPT ≤ 1.5 × ULN;

∙ Serum Cr ≤ 1 ULN, endogenous creatinine clearance rate \> 60 ml/min (Cockcroft - Gault formula);

• Male subjects and women of childbearing potential must use contraception from the start of the first dose of the study drug until 24 weeks after the last dose of the study drug;

• Normal function of major organs, with basically normal blood routine, blood biochemistry and coagulation function tests;

• The investigator believes that the patient will benefit from the treatment in terms of survival;

• The patient voluntarily participates in this study and provides a written informed consent form.